---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-23-000074"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:47:08.589128+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Denali Q1 net loss widens to $109.8M; Biogen licenses ATV:Abeta, DNL310 positive data

## Summary
- Net loss $109.8M vs $65.2M YoY; collaboration revenue $35.1M vs $42.1M.
- R&D expenses rose to $128.8M from $86.1M; cash & securities $1.29B at March 31.
- Biogen exercised option to license ATV:Abeta; Denali receives option payment and milestones.
- DNL310 Phase 1/2 interim data showed improved behavior/cognition; COMPASS study enrolling.
- Triggered $30M contingent consideration for F-star Gamma; $10M milestone from Takeda for DNL593.

## SEC filing metadata
- accession: 0001714899-23-000074
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/0001714899-23-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/dnli-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-23-000074
- JSON: https://secwatch.observer/filing/0001714899-23-000074.json
- Plain text: https://secwatch.observer/filing/0001714899-23-000074.txt

## Key facts
- Earnings Releases
  Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000074/0001714899-23-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.